Actively Recruiting
A Study of DEG6498 in Participants With Solid Tumors
Led by Degron Therapeutics Co. · Updated on 2026-05-13
100
Participants Needed
2
Research Sites
159 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? Participants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicians.
CONDITIONS
Official Title
A Study of DEG6498 in Participants With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide written informed consent before any study procedures
- Male or female aged 18 years or older at the time of consent
- Female participants must be postmenopausal, surgically sterile, or agree to use highly effective contraception during treatment and for 30 days after last dose
- Women of childbearing potential must have two negative pregnancy tests (one serum test) before starting study drug
- Male participants must agree to inform female partners to use highly effective contraception during treatment and for 30 days after last dose and avoid sperm donation during this time
- Have advanced solid tumors who have failed standard therapies or have no standard therapy available
- Part 1 includes advanced solid tumor patients
- Part 2 includes patients with BRAF mutant tumors and hepatocellular carcinoma
- Have at least one measurable lesion per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You will not qualify if you...
- Significant medical condition, laboratory abnormality, or psychiatric illness that would prevent safe participation or increase risk
- Condition that would interfere with data interpretation
- Pregnant or breastfeeding women
- Active or concurrent malignancy requiring treatment within 14 days or 5 half-lives before first dose, or antibody therapy within 28 days
- Symptomatic, neurologically unstable CNS metastases or those requiring local CNS therapy, or increasing corticosteroid doses within 2 weeks before first dose
- Clinically significant cardiovascular disease
- Active or chronic infection requiring systemic therapy within 2 weeks before first dose
- Known HIV infection, acquired immunodeficiency syndrome, or active hepatitis B or C infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
D
Degron Therapeutics Co.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here